Meta shares fall on AI restructuring report, while Lilly shrugs off Novo’s Ozempic price move
Every day during the week, Jim Crammer and CNBC Investment Club released Homestretch, a processable afternoon update at the last hour of trade at Wall Street. Markets: Wall Street retail earnings and Fed President Jay Powell weeks after a speech, the stocks do not move much on Monday. The session on Monday lacks net themes, but Meta platforms have long been promoted as a Laggard after saying that the club holding has planned the fourth restructuring of the AI team’s AI team in six months. The story is to ask questions in the light of Meta’s important investment from other technology companies to recruit AI. Novo price cut: Club name Eli Lilly shares, despite the chief rival Novo Nordisk, who reduces prices for the popular GLP-1 drug, has not changed relatively. Novo Nordisk said in a statement on Monday that the popular GLP-1 for Type 2 Diabetes, the price of Ozempic, Novocare Direct-Hasta program for patients who pay 499 dollars per month, he said. Novo also announced that it has established a goodrx to offer the same price for Özempic and Wegovy in US pharmacies. Although the news emerges that a price war warms up in a war for the market share, we do not see that this special Özempic development advances this narrative. The main reason for this is that the cash payment market for Type 2 diabetes treatment of GLP-1s is not as important for obesity colleagues. Everything comes to the scope of insurance for diabetes, which is much higher than weight loss for these drugs. Indeed, Lilly, Lillydirect platform Type 2 diabetes therapy does not offer Mounjaro, his sister Druccbound for obesity. Lilly executives were asked for the company’s call for an August earnings and Lilly USA President Ilya Yuffa said: “We have a significant scope with Mounjaro. So, both commercial and commercial and more than 90% [Medicare] Section D. and so, [adding Mounjaro to LillyDirect] It always provides additional streets. We see a significant growth with Zepbound because we have commercially coverage gaps. And frankly, we also have the ability to cover anti-celestial drugs in section D. So we see this as an opportunity to meet this need. Regardless of its value, we still love that Lilly is sitting on the obesity side of the GLP-1 market. In February, Eli Lilly announced that self -payment patients could receive single -dose bottles for $ 499 per month through the Lillydirect platform. This is equal to the price of Wegovy in Novocare. As head-to-head studies found that Lilly found that Zepbound is superior to Wegovy in Novo Nordisk’s weight loss, patients should continue to prefer Lilly’s GLP-1. Initially, because of concerns about a potential price war, we reduced our note in Eli Lilly after a few weeks ago. However, we reversed the course and raised the stock back to a purchasing equivalent to 1 following the signs of confidence directed by the important internal purchasing activity. Nuclear Winning: Alphabet’s Google and nuclear energy company Kairos Power announced on Monday that a developed nuclear power plant was deployed to the network. According to the agreement, a reactor operated by Kairos Power will offer reliable, 7/24 energy up to 50 Megawatt to the Tennessee Valley Authority electric network, which strengthens the Google data centers in Tennessee and Alabama. Electricity will come from Hermes 2 factories of Kairos, which is planned to start operations in 2030. Cooperation emphasizes how hyper scales create new partnerships with nuclear energy providers to secure slum forces towards the end of the decade. Unlike gas fuel electricity, technology giants such as nuclear energy and alphabet offer a way to operate data centers to clean energy while advanceing carbohydrate goals. The club’s name is probably known for its heavy service type gas turbines, while the energy production company makes small modular reactors that have gained popularity, so it is important to follow nuclear developments closely. Next: Palo Alto Networks reported this week after the closing Bell, the first of the three -profitable club shares. Before the opening bell on Tuesday, we will see the earnings of Club name Home Depot, Medtronic and Viking Holdings. On the data side, we will see that July houses have begun and construction permits, but we will take clues from what Home Depot Management calls for earnings in the housing industry. (See here for the full list of Jim Cramer’s philanthropist’s confidence in the charitable trust. Jim is waiting for 45 minutes after sending a trade warning before buying or selling a share in the portfolio of charitable confidence. If Jim talked about a stock on CNBC TV, he’s waiting for 72 hours after trading warning before trading. The above investment club information is subject to our conditions and conditions and our Privacy Policy with the waiver. There is no confidence or duty or not, as you receive any information provided in connection with the Investment Club. A specific result or profit is not guaranteed.
